Compounded semaglutide is not FDA approved. The FDA does not verify the safety, effectiveness, or quality of any compounded drug before it is sold. This distinction matters because the brand-name versions of semaglutide (Ozempic and Wegovy) went through years of clinical trials and manufacturing review to earn FDA approval, while compounded versions skip that entire process.
What “Not FDA Approved” Actually Means
When a drug is FDA approved, the agency has reviewed clinical trial data proving it works and is safe at specific doses, and it has inspected the manufacturing process to ensure consistency from batch to batch. Compounded drugs receive none of this scrutiny. No one tests whether a compounded semaglutide injection contains the right amount of active ingredient, whether it’s sterile, or whether it produces the same effects in your body as the brand-name version.
This doesn’t automatically mean compounded semaglutide is dangerous. Compounding pharmacies have existed for decades, filling a legitimate role when patients need customized medications, like a different dose or a formulation without a specific allergen. But with semaglutide, the scale and context are different. Millions of people want access to a weight loss drug that’s expensive and has been in short supply, and compounding pharmacies have stepped in to meet that demand.
How Compounding Pharmacies Can Legally Make It
Federal law allows two types of compounding operations, each with different rules. Understanding which type you’re dealing with affects what protections you have as a patient.
Traditional compounding pharmacies operate under Section 503A of federal law. They must fill prescriptions for individual, identified patients. A doctor writes you a prescription, and a licensed pharmacist mixes the medication specifically for you. These pharmacies are exempt from FDA manufacturing standards and new drug approval requirements, but they’re regulated by state pharmacy boards.
Outsourcing facilities operate under Section 503B. These are larger operations that can produce compounded drugs in bulk without patient-specific prescriptions. They must register with the FDA, report adverse events, and follow certain labeling rules, including printing “This is a compounded drug” on every container. They face more federal oversight than traditional pharmacies but still far less than manufacturers of FDA-approved drugs.
Here’s the critical legal wrinkle: outsourcing facilities can only compound drugs from bulk ingredients if those ingredients appear on an FDA-approved list or if the finished drug is on the FDA’s drug shortage list. As of early 2025, semaglutide no longer appears on the FDA’s shortage list. This significantly narrows the legal basis for outsourcing facilities to keep producing it. Traditional 503A pharmacies can still fill individual prescriptions, but they cannot regularly compound large quantities of drugs that are “essentially a copy” of a commercially available product. The FDA considers a compounded drug essentially a copy if it has the same active ingredient in the same or similar strength and is used the same way.
The Salt Form Problem
One of the FDA’s most specific concerns goes beyond general compounding risks. Some compounders have been using salt forms of semaglutide, specifically semaglutide sodium and semaglutide acetate, rather than the base form of semaglutide used in Ozempic and Wegovy. These are chemically different active ingredients.
The FDA has stated plainly that it has no information on whether these salt forms share the same chemical and pharmacologic properties as the approved drug, and it is “not aware of any lawful basis for their use in compounding.” The Mississippi Board of Pharmacy flagged a related issue: semaglutide does not have a standard monograph in the United States Pharmacopeia, the reference book that sets purity and quality benchmarks for drug ingredients. Without that monograph, there’s no established standard for compounders to follow. The board also warned pharmacies to check invoices carefully, noting that some bulk semaglutide being sold is research-grade product, not pharmaceutical-grade.
In practical terms, if you receive compounded semaglutide made from a salt form, you may be injecting a substance that has never been tested in humans in any clinical trial.
The Shortage That Made This Possible
Compounded semaglutide became widely available because the FDA-approved versions were in shortage for an extended period. When a drug is on the FDA’s official shortage list, compounders have broader legal authority to produce it. That window has now closed. Semaglutide was removed from the shortage list as supply from the manufacturer stabilized.
This removal triggered legal battles. A trade group representing compounding pharmacies sued the FDA over a similar decision involving tirzepatide (the active ingredient in Zepbound and Mounjaro), arguing the shortage determination was arbitrary. A federal judge sided with the FDA in that case, affirming the agency’s authority to remove drugs from the shortage list and effectively cutting off compounders’ access. The semaglutide situation follows a similar trajectory, with compounders facing an increasingly narrow legal path to continue production.
Risks Compared to the Approved Version
The risks of compounded semaglutide fall into several categories that don’t apply to the FDA-approved versions.
- Dosing inconsistency. Without FDA manufacturing oversight, there’s no guarantee each vial contains the labeled amount of semaglutide. Too little means the drug doesn’t work. Too much could intensify side effects like nausea, vomiting, or more serious complications like pancreatitis.
- Sterility concerns. Injectable medications must be sterile. FDA-approved manufacturers follow strict current good manufacturing practices. Compounding pharmacies operating under 503A are exempt from these requirements.
- Unknown ingredients. Salt forms of semaglutide have not been studied for safety or efficacy. You have no way to verify which form of semaglutide is in your injection without independent lab testing.
- No adverse event tracking for most pharmacies. Only 503B outsourcing facilities are required to report adverse events to the FDA. If you experience a problem with a compounded product from a traditional pharmacy, there’s no federal mechanism capturing that data.
How to Verify a Compounding Pharmacy
If you’re considering compounded semaglutide, the pharmacy you use matters significantly. Legitimate pharmacies require a valid prescription, are licensed in both their own state and yours, provide clear contact information for patient inquiries, and comply with privacy laws. The National Association of Boards of Pharmacy (NABP) reviews online pharmacies and flags those that don’t meet safety standards. Websites ending in “.pharmacy” have been accredited by NABP, and unlike logos or seals, that domain suffix cannot be faked.
Red flags include any pharmacy willing to sell you semaglutide without a prescription, sites that don’t list a physical address or pharmacist contact, and prices that seem dramatically lower than other compounders. In NABP reviews, 96% of illegal online pharmacies did not require a valid prescription for prescription-only medications.